Evidence map›Paper›PMID 38922176›Full record

ArticleToxins2024

Botulinum Toxin and Deep Brain Stimulation in Dystonia.

Julia Carvalhinho Carlos de Souza, Ananda Carolina Moraes Falcone, Renata Montes Garcia Barbosa, Miriam Carvalho Soares, Renato Munhoz, Marina Farah, Tamine Capato, Sara Carvalho Barbosa Casagrande, Marcela Ferreira Cordellini, Gabriel de Castro Micheli and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Introduction toToxins · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Julia Carvalhinho Carlos de SouzaMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.
Ananda Carolina Moraes FalconeMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.
Renata Montes Garcia BarbosaMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.ORCID 0009-0007-3814-691X
Miriam Carvalho SoaresMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.ORCID 0000-0002-3725-4464
Renato MunhozMorton and Gloria Shulman Movement Disorders Centre and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, University Health Network, Toronto, ON M5T 2S8, Canada.
Marina FarahCajuru University Hospital, Pontíficia Universidade Católica do Paraná, Curitiba 80050-350, Brazil.
Tamine CapatoMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.ORCID 0000-0003-4235-4141
Sara Carvalho Barbosa CasagrandeMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.
Marcela Ferreira CordelliniInstituto de Neurologia de Curitiba, Curitiba 81210-310, Brazil.ORCID 0000-0002-1603-1990
Gabriel de Castro MicheliDepartment of Neurology, University Hospital Clementino Fraga Filho, Federal University of Rio de Janeiro, Rio de Janeiro 21941-617, Brazil.
João Carlos Papaterra LimongiMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.
Egberto Reis BarbosaMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.
Clarice ListikMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.
Rubens Gisbert CuryMovement Disorders Center, Department of Neurology, School of Medicine, University of São Paulo, São Paulo 05403-000, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deep Brain Stimulation (DBS) is a recognized treatment for different dystonia subtypes and has been approved by the Food and Drug Administration (FDA) since 2003. The European Federation of Neurological Societies (EFNS) and the International Parkinson and Movement Disorders Society (MDS) recommend DBS for dystonia after failure of botulinum toxin (BoNT) and other oral medications for dystonia treatment. In addition, several long-term studies have demonstrated the continuous efficacy of DBS on motor and quality of life (QoL) scores. However, there are only a few reports comparing the overall impact of surgical treatment in BoNT protocols (e.g., dosage and number of selected muscles before and after surgery). This retrospective multicenter chart-review study analyzed botulinum toxin total dosage and dosage per muscle in 23 dystonic patients before and after DBS surgery. The study's primary outcome was to analyze whether there was a reduction in BoNT dosage after DBS surgery. The mean BoNT dosages difference between baseline and post-surgery was 293.4 units for 6 months, 292.6 units for 12 months, and 295.2 units at the last visit. The median total dose of BoNT in the preoperative period was 800 units (N = 23). At the last visit, the median was 700 units (

Indexed as

Deep Brain StimulationDystoniaAdultAgedBotulinum ToxinsFemaleHumansMaleMiddle AgedQuality of LifeRetrospective StudiesTreatment OutcomeBotulinum Toxinsabobotulinum toxinAbotulinum toxinDeep Brain Stimulationdystoniaonabotulinum toxinA

Identifiers

PMID38922176
PMCPMC11209614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.